Financials in USD. Standardized financial statements.
A compact view of how Vaccinex, Inc. turns revenue into operating income and net income.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $601,000 | $570,000 | $100,000 | $900,000 | $50,000 | $523,000 | $724,000 | $90,000 | $316,000 |
| Revenue Growth? | +5.4% | +470.0% | -88.9% | +1700.0% | -90.4% | -27.8% | +704.4% | -71.5% | 0.0% |
| Cost of Revenue? | $0 | $0 | $207,000 | $169,000 | $2,000 | $199,000 | $1.03M | $160,000 | $115,000 |
| Gross Profit? | $601,000 | $570,000 | $68,000 | $731,000 | $48,000 | $324,000 | -$309,000 | -$70,000 | $201,000 |
| Gross Margin? | +100.0% | +100.0% | +68.0% | +81.2% | +96.0% | +62.0% | -42.7% | -77.8% | +63.6% |
| Operating Expenses? | $19.34M | $23.45M | $20.01M | $23.22M | $28.38M | $32.34M | $26.97M | $21.03M | $20.46M |
| Operating Income? | -$18.73M | -$22.89M | -$19.91M | -$22.49M | -$28.33M | -$32.02M | -$27.28M | -$21.10M | -$20.26M |
| EBITDA? | -$18.54M | -$19.75M | -$19.61M | -$21.40M | -$28.05M | -$31.61M | -$28.90M | -$17.20M | -$10.78M |
| Income Before Tax | -$18.63M | -$20.25M | -$19.82M | -$22.38M | -$28.85M | -$31.86M | -$29.52M | -$18.76M | -$13.94M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income? | -$18.63M | -$20.25M | -$19.72M | -$22.38M | -$28.85M | -$32.02M | -$29.52M | -$18.72M | -$13.94M |
| EPS? | $-8.88 | $-43.68 | $-97.59 | $-163.80 | $-322.50 | $-521.95 | $-1186.70 | $-689.86 | $-526.85 |
| Diluted EPS? | $-8.88 | $-43.68 | $-97.59 | $-162.91 | $-322.50 | $-521.95 | $-1186.70 | $-689.86 | $-526.85 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality